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Control of rat glomerular microcirculation by juxtaglomerular
adenosine A1 receptors. The role of adenosine A1 receptors in the
glomerular microcirculation and tubuloglomerular feedback
(TGF) was studied in anesthetized Sprague-Dawley rats. TGF
activity was assessed as the reduction in proximal tubular stop-
flow pressure (SFP) on establishing orthograde perfusion of the
loop of Henle with artificial tubular fluid at 40 nl/min. Adminis-
tration of a selective A1 receptor antagonist, KW-3902 (0.5
mg/kg/min i.v.), increased fractional excretion of Na (FENa)
4.3-fold without changing blood pressure, glomerular filtration
rate, renal plasma flow, or filtration fraction. SFP in the absence
of distal flow (SFP0) increased, and TGF-mediated SFP reduction
was suppressed dose dependently [by 23 6 2% from an SFP0 of 34
6 1 mm Hg, by 15 6 4% from 36 6 2 mm Hg, and by 2 6 1% from
39 6 1 mm Hg during vehicle, low- and high-dose infusions (0.5
and 5.0 mg/kg/min), respectively]. Intratubular or peritubular
capillary administration of 1024 M KW-3902 completely sup-
pressed TGF without affecting SFP0. TGF suppression and
elevation of SFP0 during systemic A1 blockade indicated vasodi-
lation, both in the afferent arteriole and more proximal preglo-
merular vessels. Inhibition of tubular Na reabsorption combined
with TGF suppression allowed the marked natriuresis. TGF
suppression through systemic, luminal, and peritubular applica-
tion of the drug suggest that juxtaglomerular apparatus A1
receptors are important in the control of glomerular microcircu-
lation.
Glomerular hemodynamics are controlled by tubuloglo-
merular feedback (TGF), which alters blood flow and
glomerular filtration rate (GFR) in a single nephron by
changing afferent arteriolar resistance in response to the
[NaCl] at the macula densa (MD). Endogenous vasoactive
substances contribute to the regulation of afferent arterio-
lar tone and thus modulate TGF responsiveness [1, 2].
Adenosine, endogenously produced as a metabolite of
adenosine triphosphate, is held to be a modulator of renal
hemodynamics and tubular function and a candidate for
TGF mediation. Adenosine A1 receptors exist in the
juxtaglomerular apparatus (JGA) [3]. We investigated the
role of adenosine A1 receptor in glomerular microcircula-
tion and TGF in anesthetized rats.
METHODS
Male Sprague-Dawley rats kept on commercial chow
were anesthetized (thiopental sodium, Ravonal, 110 mg/kg
i.p.) and prepared as previously described [4]. Polyfruc-
tosan (10% in 0.9% saline; Inutest, Laevosan, Austria) was
infused i.v. at 4.5 ml/kg/hr. Arterial pressure was monitored
and blood sampled through the right femoral artery. The
left kidney was prepared for micropuncture, and the ureter
was cannulated at the pelvis to collect urine samples. A
25-gauge needle connected to a PE-50 tube was inserted
into the left renal vein to collect renal venous blood.
Clearances were measured during i.v. administration of a
specific adenosine A1 receptor antagonist, KW-3902 [5], at
0.5 mg/kg/min.
The TGF response was assessed as the change in proxi-
mal stop-flow pressure (SFP), an index of intraglomerular
pressure (Pgc), on establishing orthograde perfusion of the
loop of Henle with artificial tubular fluid (ATF) from the
last accessible proximal segment at 40 nl/min. The response
was assessed during i.v. infusion of KW-3902 at 0.5 or 5.0
mg/kg/min; during loop perfusion at 40 nl/min with 1024 M
KW-3902 in ATF and during peritubular capillary micro-
infusion of 1024 M KW-3902 in 0.9% saline at 20 nl/min.
Glomerular filtration rate, renal plasma flow (RPF), and
renal blood flow were calculated using standard formulas
and renal vascular resistance as mean blood pressure/renal
blood flow. Results are expressed as mean 6 SEM. Student’s
paired or unpaired t-test or analysis of variance was used
for comparison. P , 0.05 was considered statistically sig-
nificant.
RESULTS AND DISCUSSION
KW-3902 (0.5 mg/kg/min i.v.) increased urine flow by
38%, fractional excretion of Na (FENa) 4.3-fold, and FEK
by 34% without changing mean blood pressure, GFR, RPF,
or filtration fraction. During vehicle infusion, SFP in the
absence of distal flow (SFP0) was 34 6 1 mm Hg and fell on
loop perfusion by 23 6 2%. Systemic KW-3902 at low and
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high doses (0.5 and 5.0 mg/kg/min) increased SFP0 to 36 6
2 and 39 6 1 mm Hg and suppressed TGF-mediated SFP
reduction to 15 6 4% and 2 6 1%, respectively. Intralu-
minal KW-3902 completely suppressed the TGF response:
SFP remained unchanged from 35 6 1 to 34 6 2 mm Hg
during loop perfusion with 1024 M KW-3902 in ATF,
whereas SFP decreased from 34 6 1 to 26 6 1 mm Hg
during vehicle application. Microinfusion of 1024 M KW-
3902 at 20 nl/min into peritubular capillary of the tested
nephron suppressed the SFP response to loop perfusion;
SFP remained unchanged from 36 6 1 to 34 6 2 mm Hg,
whereas SFP was reduced from 35 6 1 to 28 6 2 mm Hg
before KW-3902 infusion and from 35 6 2 to 29 6 2 mm
Hg in the recovery period.
Our findings show that intravenous, intraluminal, and
peritubular administration of a selective A1 receptor an-
tagonist, KW-3902, decreases the maximal reduction in
SFP induced by loop perfusion, indicating attenuation of
TGF response. Because the TGF response involves the
vasomotor response of the afferent arteriole, the blunted
response of TGF suggests dilation of this arteriolar seg-
ment by KW-3902. This is in accordance with results from
in vitro isolated arterioles of rabbit kidneys in which
afferent arteriolar constriction induced by an adenosine
analog is reversed completely by coadministration of a
selective A1 antagonist [6]. On the other hand, i.v. admin-
istration of adenosine receptor antagonists does not affect
the TGF response [7, 8], whereas intraluminal administra-
tion clearly inhibits TGF [7]. The discrepancy between
these results and this study may be due to the low selectivity
Fig. 1. Effects of A1 receptor antagonist, KW-
3902, on the reduction in proximal stop-flow
pressure (SFP) by loop of Henle perfusion with
artificial tubular fluid (ATF). (A) Systemic (0.5
or 5.0 mg/kg/min i.v.), (B) intratubular (1024 M
in ATF), or (C) peritubular capillary (1024 M in
0.9% saline) application of KW-3902
significantly suppressed TGF-mediated SFP
reduction. Open circles with bars represent the
means 6 SEM. *P , 0.05 versus zero perfusion.
†P , 0.05 versus corresponding value in vehicle.
Kawabata et al: A1 receptor and TGF S-229
for the A1 receptor of the agent used [7] or volume
replacement by plasma [8], which is known to attenuate the
TGF response.
In this study, A1 receptor blockade with KW-3902, via
peritubular capillary or tubular lumen, suppressed TGF-
mediated SFP reduction but did not alter SFP0 (that is, in
the absence of TGF control). This indicates that A1
blockade via these routes does not affect the basal tone of
the afferent arterioles and that the effect of A1 blockade
becomes evident only when TGF mechanism is stimulated.
Because these two routes of application deliver the agent
through capillary wall or tubular cells into the interstitium
surrounding the glomerular vessels, thus avoiding systemic
effects, our results suggest that endogenous adenosine and
its A1 receptor activation in the JGA serve as the commu-
nication link between MD cells and afferent arterioles to
activate the TGF mechanism.
In addition to TGF suppression, systemic A1 blockade
elevated SFP, implying an increase in Pgc in the absence of
TGF control. This suggests vasodilation of proximal pre-
glomerular vessels in addition to the afferent arteriole in
which, at the entrance into the glomerulus, the TGF-
mediated vascular response occurs. Furthermore, systemic
A1 receptor antagonism stimulates the renin-angiotensin
system, which may elevate Pgc through the vasoconstriction
of efferent arterioles [8].
Intravenous KW-3902 induced a marked natriuresis
without affecting any whole-kidney hemodynamic parame-
ters, indicating the inhibition of sodium reabsorption in
tubular site(s). A1 receptor mRNA is found widely along
nephron segments [9], and A1 receptor-mediated tubular
effects have been shown in in vitro preparations of the
proximal convoluted tubule using a selective A1 antagonist,
FK453 [10]. However, inhibition of proximal reabsorption
alone would result in the increase in fluid delivery into the
loop of Henle. This, through the activation of TGF, de-
creases GFR and thereby attenuates the natriuresis. In this
study, TGF-mediated SFP reduction was suppressed, and
SFP without loop perfusion dose dependently increased.
Inhibition of tubular sodium reabsorption combined with
the effects on glomerular microcirculation is suggested to
be the mechanism of the marked natriuresis by KW-3902.
In addition, these findings agree with observations that
intravenous infusion of a nonxanthine, selective A1 antag-
onist, FK838, suppresses TGF-mediated reduction in early
proximal flow rate, an index of single nephron GFR, and
also induced natriuresis without affecting GFR or RPF
[11], suggesting a common mechanism in natriuresis
through systemic A1 receptor antagonism.
In conclusion, a selective A1 antagonist KW-3902 antag-
onizes MD-mediated afferent arteriolar vasoconstriction
and thus suppresses TGF. TGF suppression through sys-
temic, luminal, and peritubular application of the drug
suggests that the activation of A1 receptor in JGA by
endogenous adenosine plays an important role in the
control of glomerular microcirculation. The marked natri-
uresis, induced by direct effects on tubular A1 receptors,
combined with effects on intrarenal arterioles, implies a
role for A1 receptors in renal sodium handling.
APPENDIX
Abbreviations used in this article are: ATF, artificial tubular fluid; FENa,
fractional excretion of Na; GFR, glomerular filtration rate; JGA, juxta-
glomerular apparatus; MD, macula densa; RPF, renal plasma flow; SFP,
stop-flow pressure; TGF, tubuloglomerular feedback.
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